<DOC>
	<DOCNO>NCT00054327</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When stem cell related donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well give chemotherapy without radiation therapy follow donor stem cell transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine standard approach hematopoietic stem cell transplantation match unrelated donor patient hematologic malignancy . - Determine toxicity regimen patient . - Determine relapse rate survival rate patient treat regimen . - Correlate incidence severity graft-versus-host disease relapse survival patient treat regimen . OUTLINE : Patients receive 1 follow preparative regimen : - Regimen A : Patients receive cytarabine IV 1 hour twice daily day -9 -7 cyclophosphamide IV 2 hour day -6 -5 . Patients also undergo total body irradiation ( TBI ) twice daily day -4 -1 . - Regimen B-1 : Patients receive cyclophosphamide IV TBI regimen A . - Regimen B-2 : Patients receive cyclophosphamide IV 2 hour day -5 -4 . Patients also undergo TBI twice daily day -3 -1 . - Regimen B-3 : Patients receive TBI day -7 -5 . Patients receive cyclophosphamide IV day -4 -3 . - Regimen C : Patients receive oral busulfan 4 time daily day -8 -5 cyclophosphamide IV 2 hour day -4 -2 . - Regimen D : Patients receive TBI day -6 -4 . Patients receive etoposide infusion day -3 . All patient undergo stem cell transplantation match , unrelated donor day 0 . Patients follow weekly 100 day , 6 month , every 6 month 2.5 year . PROJECTED ACCRUAL : 50</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Eligibility Criteria : 1 . Patients histologic confirmation follow disease eligible : 1 . AML first , second great remission 2 . AML early relapse , define &lt; 30 % marrow blast 3 . ALL second great complete remission 4 . High risk ALL first complete remission , high risk define presence ( 4 ; 11 ) , ( 9 ; 22 ) , ( 8 ; 14 ) translocation , patient present extreme hyperleukocytosis ( initial WBC &gt; 500 K/ml ) failure achieve complete remission standard induction therapy . 5 . CML 6 . Myelodysplastic syndrome ( include evolution AML , e.g. , Refractory Anemia Excess Blasts ( RAEB ) , Refractory Anemia Excess Blasts transformation ( RAEBt ) . 7 . Lymphoma ( intermediate high grade ) chemosensitive ( CR PR ) first great relapse chemosensitive first line therapy achieve PR . 8 . Hematologic Disease Inherited Immunodeficiencies 9 . Hodgkin 's disease , relapse refractory standard treatment . 2 . Patients must less equal 55 year age . 3 . Patients ( guardian minor ) must able give informed consent . Children old 11 year age must assent process . 4 . Patients guardian must demonstrate proofofpayment . 5 . Patients must ECOG Performance Status 2 less . ( See Appendix I ) 6 . Patients must evidence active infection time transplantation . 7 . Patients must HIV nonreactive . 8 . Patients must pretransplant , multiorgan assessment prior transplantation follow outcome : 1. rest ejection fraction 50 % great ( shorten fraction great 28 % small child ) . 2 . Diffusion capacity 50 % great predict , FEV1 50 % great , P2O 80 mm Hg demonstrate pulmonary function test . 3. serum creatinine less equal 2.0 mg/dL and/or correct creatinine clearance 50 ml/min great 24 hr urine . 4 . A total bilirubin le 2.5 mg/dL AST le 4 time upper limit normal . 9 . Females childbearing age may pregnant lactate must current negative pregnancy test Ineligibility Criteria : Patients life expectancy less three month therapy . Patients ECOG performance status great 2 , ( See Appendix I ) Lansky Scale &lt; 70 % . Patients angina and/or congestive heart failure require treatment , myocardial infarction within past year . Patients rest ejection le 50 % ( shorten fraction le 28 % ) clear transplant cardiology Patients severe renal disease demonstrate serum creatinine great 2.0 mg/dL and/or correct creatinine clearance le 50 ml/min . ( correct BSA 1.73 mÂ¬2 ) Patients complication make risk death transplantation nonmalignant cause great risk relapse . Patients active infection soft tissue infection , sinus infection , dental infection , fungal infection hepatitis include chronic active hepatitis ; infection successfully treat , patient may reconsider transplantation later date . Patients decrease pulmonary function due disorder demonstrate diffusion capacity le 50 % predict , FEV1 le 50 % predict PO2 le 80 mm Hg pulmonary function test . Patients decrease liver function demonstrate total bilirubin great 2.5 mg/dL and/or AST great 4 time upper limit normal . Patients diabetes mellitus consider casebycase basis . However , patient diabetes control medical management ineligible . Patients significant psychiatric illness consider case bycase basis . With patient 's consent , Mental Health Care worker assist manage transplant physician determine patient safely undergo transplantation comply followup recommendation . Psychosocial assessment bone marrow transplant team may identify individual form therapy may contraindicate . This decision base upon estimate adequacy patient support system prediction patient 's compliance medication , require diagnostic procedure and/or followup care . Females childbearing age may pregnant lactate must current negative pregnancy test Patients stem cell transplant less one year earlier</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>